A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine

The goal of this clinical study is to investigate how safe and effective it is to receive both the Fluzone® High-Dose (HD) influenza vaccine and CD388, a long-acting antiviral medicine, at the same time. Some participants will receive the vaccine and CD388, while others will receive the vaccine and a placebo. The study aims to determine whether taking CD388 together with the flu vaccine affects the body's ability to build protection-called an immune response-against the flu, as compared to getting the vaccine with a placebo. The hypothesis is that giving both at the same time does not weaken the immune response to the vaccine. The study will measure the amount of antibodies (proteins produced by the immune system to fight flu viruses) generated by participants in both groups to check that CD388 does not interfere with how well the vaccine works. Participants will also be closely watched for any side effects or reactions to check that CD388 is safe to take alongside the vaccine. Expanded access to the study treatments (flu vaccine and CD388) will not be provided to participants after the study ends.

NCT Number	NCT07300085
Lead Sponsor	Cidara Therapeutics Inc.
Conditions	Healthy Participants
Enrollment	100 participants
Start Date	2025-11-08
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-24